Skip to main content

Table 2 Univariate and multivariate Cox regression of loss of functional hearing in 57 patients

From: Progression of hearing loss after LINAC-based stereotactic radiotherapy for vestibular schwannoma is associated with cochlear dose, not with pre-treatment hearing level

GR class I&II,

n = 57

Univariate

Multivariate

Hr

95% CI Lower

95% CI Upper

p-value

HR

95% CI Lower

95% CI Upper

p-value

Age

1.03

1.005

1.06

0.017

   

n.s.

PTA pre treatment

1.072

1.04

1.11

< 0.001

1.081

1.045

1.118

< 0.001

Tumor diameter CPA (cm)

0.72

0.47

1.12

0.15

   

n.s.

Tumor diameter IAC (cm)

2.70

0.93

7.85

0.07

   

n.s.

Tumor Volume pre- treatment (ml)

0.94

0.86

1.03

0.17

   

n.s.

Dose scheme (0 = fract, 1 = rs)

2.05

1.01

4.17

0.05

   

n.s.

Max cochlear dose EQD2a

1

1

1

0.99

   

n.s.

Mean cochlear dose EQD2a

1

1

1

0.58

   

n.s.

V90 cochlea EQD2 b

1.01

1.00

1.013

0.027

1.011

1.004

1.017

0.001

Cochlear volume (ml)

1.0

0.99

1.003

0.26

   

n.s.

time-to-first-audiogram (after treatment)

1.0

0.95

1.04

0.85

   

n.s.

  1. n.s. Not significant, 95% CI = 95% confidence interval, PTA Pure tone average
  2. aper cGy,
  3. bper mm3